Go Deep
Skye Bioscience, Inc.
Skye Bioscience, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -23,521 | -0.2 | -14.16 | 0.01 | 150.60 |
| Oct 2026 | -23,328 | -0.2 | -13.80 | 0.01 | 146.81 |
| Oct 2026 | -25,031 | -0.2 | -13.62 | 0.01 | 145.07 |
| Oct 2026 | -25,466 | -0.2 | -14.42 | 0.01 | 153.60 |
| Oct 2026 | -25,514 | -0.2 | -14.51 | 0.01 | 154.17 |
| Oct 2026 | -25,466 | -0.2 | -14.42 | 0.01 | 152.91 |
Skye Bioscience, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -10,786,594.0 | -12,509,361.0 | -14,441,963.0 | -12,754,660.0 |
| EPS | -0.3 | -0.3 | -0.4 | -0.3 |
Skye Bioscience, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -55,924,814.0 | -26,567,123.0 | -37,644,784.0 | -19,481,602.0 | — |
| EPS | -1.4 | -0.7 | -5.4 | -8.8 | — |
Skye Bioscience, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 28,313,633.0 | 72,763,773.0 | 11,940,411.0 | 9,111,072.0 | — |
| Total Liabilities | 8,289,458.0 | 4,612,049.0 | 14,072,229.0 | 12,119,126.0 | — |
| Total Equity | 20,024,175.0 | 68,151,724.0 | -2,131,818.0 | -3,008,054.0 | — |
Owes vs Owns
Skye Bioscience, Inc. owed $1.05 for every $1 it owned in Jun 2026, down from $1.33 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.05× | 0.29× | 0.06× | 1.18× | 1.33× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Skye Bioscience, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 90.9%Fixed assets (tangible) 4.1%Other assets 4.9%
How it's funded — Dec 2025
Short-term debt 0.7%Payables 7.2%Other liabilities 21.1%Shareholders' equity 70.7%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 25.7 | 68.4 | 1.3 | 1.2 |
| Receivables | 0.0 | 0.0 | 0.2 | 0.1 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 1.2 | 1.9 | 0.3 | 0.2 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 1.4 | 2.5 | 10.2 | 7.6 |
| Liabilities & equity | ||||
| Short-term debt | 0.2 | 0.2 | 4.4 | 1.9 |
| Long-term debt | 0.1 | 0.3 | 0.2 | 0.0 |
| Payables | 2.0 | 0.6 | 1.0 | 1.8 |
| Other liabilities | 6.0 | 3.6 | 8.6 | 8.4 |
| Shareholders' equity | 20.0 | 68.2 | -2.1 | -3.0 |
| Net tangible assets | 20.0 | 68.2 | -2.1 | -3.0 |
Skye Bioscience, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -43,062,529.0 | -25,237,480.0 | -13,952,178.0 | -12,744,072.0 | — |
| Investing Activities | -19,500,285.0 | -245,615.0 | 6,596,456.0 | 5,214,395.0 | — |
| Financing Activities | 29,571.0 | 83,562,181.0 | 16,443,270.0 | -208,794.0 | — |